An analysis of the FINEARTS-HF trial, which showed finerenone's benefits in heart failure outcomes, shows no significant ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.50. The company’s shares opened today at ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

North Carolina is a leading place for biotech, and a big part of that success comes from GlaxoSmithKline (GSK). This global ...

Me continues to face challenges in maintaining its revenue and captures growth. Click here to read why ME stock is a Sell.

Research Triangle Park (RTP) is widely recognized as one of the foremost innovation hubs in the United States. Situated ...

Global Cocaine Intoxication Treatment MarketThe global cocaine intoxication treatment market is projected to achieve a ...

The growth of the Chronic Hepatitis B Virus Testing market can be attributed to several key factors, including significant ...

Treatment MarketThe global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, ...

On Oct. 26, 1944, after four days of furious fighting, the World War II battle of Leyte Gulf, largest air-naval clash in ...

The growth of the DEE treatment market can be attributed to the increasing prevalence of developmental and epileptic ...